India 10-year bond yield fell 0.41 per cent to 5.89 after trading in 5.87-5.91 range NEW DELHI: The Nifty Pharma index traded ...

Discover the Dr Reddys Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Dr. Reddy's Laboratories Ltd. closed 14.27% below its 52-week high of 1,420.20 rupees, which the company achieved on August ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Q3 2025 Earnings Call Transcript January 23, 2025 Operator: Ladies and gentlemen, good day and welcome to the Quarter Three ...

Dr. Reddy's Laboratories Ltd. closed 16.92% below its 52-week high of 1,420.20 rupees, which the company reached on August ...

Crossmark Global Holdings Inc. grew its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by 328.3% in the fourth quarter, Holdings Channel reports. The firm owned 12,760 ...

Barclays analyst Balaji Prasad maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report) today and set a price target of ...

Dr Reddy’s Laboratories CEO expressed a "very positive outlook" for the Indian pharmaceutical industry despite potential ...

Shares of Dr Reddy's Laboratories fell by 5% as the company's third-quarter profit rise failed to impress investors. The ...

Indian shares inched higher on Friday, tracking Asian peers after U.S. President Donald Trump said he would push for lower interest rates, while worries over moderation in domestic earnings capped ...

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.